Strategy Thesis
momentum-code applies one of the oldest reliable edges in equity markets: buying recent outperformers. The rule is simple — scan a 24-name large-cap universe (tech, financials, healthcare, consumer, energy, industrials), identify the top positive movers, and enter capped positions. No short side, no leverage. The simplicity is intentional; complex rules overfit, and this strategy is designed to be legible and auditable.
Deployment Activity
The strategy went live on May 31, 2026, receiving a $10,000 allocation. Initial execution placed three trades:
| Symbol | Shares | Price |
|---|---|---|
| MSFT | 4 | $450.24 |
| HON | 8 | $237.86 |
| BAC | 38 | $51.60 |
After three fills, remaining cash sits at $4,335 — roughly 43% of the allocation — suggesting either the position cap was reached or fewer than the maximum number of qualifying movers were present at entry. The reviewer approved the strategy at zero risk score, consistent with its classification as a hand-written built-in rather than an LLM-generated candidate.
Backtest Performance
Over 451 days (approximately 15 months), the full-period backtest shows:
- Total return: 19.76% (final equity $11,976 on $10,000)
- CAGR: 10.6%
- Sharpe ratio: 0.65
- Max drawdown: 20.48%
- Turnover: 92.74% — the strategy rotates aggressively
- Total fees: $5 (negligible)
The 0.65 Sharpe is modest but not unusual for a pure long momentum strategy running through a period that included significant market volatility. The 20.5% max drawdown is the main concern — it implies the strategy can lose roughly a fifth of its value peak-to-trough, which requires conviction to hold through.
Walk-Forward Validation
The four-fold walk-forward breakdown is where the picture gets more interesting:
| Fold | Period | Return | Sharpe | Max DD |
|---|---|---|---|---|
| 1 | Aug 2024 – Jan 2025 | 15.38% | 2.47 | 6.12% |
| 2 | Jan 2025 – Jul 2025 | 3.27% | 0.46 | 16.55% |
| 3 | Jul 2025 – Dec 2025 | 12.18% | 2.31 | 5.21% |
| 4 | Dec 2025 – May 2026 | 13.71% | 1.93 | 6.32% |
All four folds are positive — a meaningful consistency signal. Three of the four show Sharpe ratios above 1.9, and the most recent fold (which serves as the out-of-sample period) returned 13.71% with a 1.93 Sharpe. That out-of-sample Sharpe is notably better than the full-period figure, which is the opposite of the typical overfitting pattern.
Fold 2 is the outlier: 3.3% return, a 0.46 Sharpe, and a 16.5% drawdown. January–July 2025 was a turbulent stretch for U.S. equities, and momentum strategies are known to suffer sharp reversals when market leadership rotates quickly.
Why Validation Did Not Pass
Despite the positive fold record, the strategy has not passed the platform's validation gate. The Deflated Sharpe Ratio (DSR) of 0.338 is the likely culprit — the platform adjusts for the number of trials (6 here), and with a modest in-sample Sharpe of 0.648, the probability that the edge is real after trial-count adjustment falls below threshold. The Probabilistic Sharpe Ratio (PSR) of 0.811 is reasonable but DSR applies a stricter multiple-testing correction.
This is the platform's overfitting guard working as intended. A strategy with only 5 trades in the backtest and 6 parameter trials doesn't yet have enough statistical mass to earn unconditional confidence.
Outlook
momentum-code has a credible thesis, consistent directional returns across all walk-forward folds, and a promising recent out-of-sample period. The validation flag is a caution, not a condemnation — more live trading data will either confirm or erode the edge. Fold 2's drawdown profile is worth watching closely as the next volatile rotation arrives.